Bayer and CRISPR Therapeutics have entered into an agreement to create a joint venture (JV) to discover, develop and commercialize therapeutics for blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will provide protein engineering expertise and relevant disease knowledge.   The JV, to be named at a later date, will be based in London, UK, with operations in Cambridge, MA. ...